Jun 15, 2020
Impel NeuroPharma Presents Data From INP104 Clinical Program In Acute Migraine At The 2020 American Headache Society (AHS) Virtual Annual Scientific Meeting
May 18, 2020
Biohaven Showcases Clinical and Pharmacoeconomic Data for NURTEC(TM) ODT (rimegepant) with 25 Presentations on the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform
Feb 27, 2020
Nuvo Pharmaceuticals® Announces Health Canada Approves Suvexx(TM) For The Acute Treatment of Migraine
Jan 31, 2020
Lilly's REYVOW(TM) (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription
Dec 04, 2019
Allergan Announces Positive Phase 3 ACHIEVE I Trial Results for Ubrogepant Published in The New England Journal of Medicine
Nov 29, 2019
World Migraine Therapeutics Market Study 2019-2024 - Triptans Projected to Grow at a Healthy CAGR
Oct 11, 2019
FDA approves new treatment for patients with migraine
Oct 11, 2019
Lilly's REYVOW(TM) (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval
Sep 26, 2019
Currax(TM) Pharmaceuticals LLC Announces First Acquisition: Acquires North American Rights to ONZETRA® Xsail®
Jul 20, 2019
Upsher-Smith Laboratories Completes Acquisition Of Two Treatments For Acute Migraine In Adults
Jul 11, 2019
Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting Demonstrating Efficacy in Multiple Patient Types and Long-term Safety
Oct 17, 2018
Allergan Announces Completion of Two Positive Safety Studies for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine
Sep 06, 2018
Biohaven Presents at Migraine Trust International Symposium and Highlights Positive Results from Study 301 and Study 302 of Rimegepant, an Oral CGRP Receptor Antagonist, in the Acute Treatment of Migraine
Jun 29, 2018
Amneal Announces Favorable Ruling Regarding Patent Validity for Zomig® (zolmitriptan) Nasal Spray
Jun 27, 2018
Promius Pharma Announces Migraine Presentations at the 60th Annual Scientific Meeting of the American Headache Society
May 17, 2018
FDA Approves Aimovig(TM) (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention
Jan 11, 2018
Global Migraine Market Spotlight 2017-2027: Key Pipeline and Marketed Drugs, Clinical Trials, Upcoming and Regulatory Events, and Patent Information
Nov 27, 2017
Biohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist Rimegepant
Nov 15, 2017
Promius Pharma Announces ZEMBRACE® SymTouch® (Sumatriptan Injection) 3 mg Achieves Primary Endpoint in Post-Approval Clinical Trial
Oct 30, 2017
Upsher-Smith's Parent Company Enters Into Agreement With Astrazeneca To Manufacture And Market Migraine Medication In Japan